Silence Therapeutics (SLN) Non-Current Assets: 2019-2025
Historic Non-Current Assets for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $13.2 million.
- Silence Therapeutics' Non-Current Assets fell 14.69% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year decrease of 14.69%. This contributed to the annual value of $15.3 million for FY2024, which is 6.31% down from last year.
- Per Silence Therapeutics' latest filing, its Non-Current Assets stood at $13.2 million for Q3 2025, which was down 21.12% from $16.7 million recorded in Q2 2025.
- Silence Therapeutics' Non-Current Assets' 5-year high stood at $16.7 million during Q2 2025, with a 5-year trough of $12.5 million in Q3 2022.
- Moreover, its 3-year median value for Non-Current Assets was $15.4 million (2024), whereas its average is $14.8 million.
- As far as peak fluctuations go, Silence Therapeutics' Non-Current Assets climbed by 28.49% in 2023, and later decreased by 14.69% in 2025.
- Silence Therapeutics' Non-Current Assets (Quarterly) stood at $13.3 million in 2021, then declined by 4.58% to $12.7 million in 2022, then rose by 28.49% to $16.3 million in 2023, then dropped by 6.31% to $15.3 million in 2024, then dropped by 14.69% to $13.2 million in 2025.
- Its Non-Current Assets stands at $13.2 million for Q3 2025, versus $16.7 million for Q2 2025 and $15.5 million for Q1 2025.